ASH Research Collaborative SCD Community Engagement Workshops

If you or a loved one is living with sickle cell disease, we want to hear from you!

The ASH Research Collaborative (ASH RC) is a non-profit organization that was established by the American Society of Hematology (ASH) in 2018 to foster collaborative partnerships to accelerate progress in hematology, with the goal of improving the lives of people affected by blood diseases. Building on the “nothing for us without us” theme that the community emphasizes, the network’s initial activities will focus on working directly with the SCD community.

Please click here to find out more!

Thank you!

(If the “click here to find out more” link doesn’t work, try clicking here:

For more information about ASH RC, visit or contact ASH RC staff.

Share this post

Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."